| Ytd | -44.51% | |
| 1y | -17.60% |
| Open | 1.88 | Prev Close | 1.86 | Low | 1.87 | High | 1.96 | Mkt Cap | 81.68M |
| Vol | 708.78K | Avg Vol | 1.23M | EPS | -1.71 | P/E | N/A | Forward P/E | -2.77 |
| Beta | 1.70 | Short Ratio | 6.21 | Inst. Own | 8.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.95 | 200-d Avg | 2.54 | 1yr Est | 34.80 |
ANVS News
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Co
Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per sha
Shares of 8x8 Inc (NASDAQ: EGHT) jumped 13.3% in pre-market trading after reporting better-than-expe
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst cons
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic prote
Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout antici
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage
NeuroRPM, a digital health company focused on Parkinson's disease monitoring, today announced th
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.39) per share which missed the analyst cons
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical dr
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical d
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, wit
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical d
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.37) per share which missed the analyst cons
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical d
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical dr
Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and mainta
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical dr
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy a
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.32) per share which beat the analyst consen
Annovis achieves comprehensive intellectual property (IP) protection now covering both the original
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical dr
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy a
https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzh
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed t
Tuesday saw 132 companies set new 52-week lows.
On Wednesday, 311 stocks hit new 52-week lows.
Friday's session saw 112 companies set new 52-week lows.
U.S. stocks traded mixed, with the Dow Jones gaining around 200 points on Monday. Here are some big
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday
During Thursday, 849 stocks hit new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
On Monday, 524 stocks hit new 52-week lows.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched
On Friday morning, 126 companies achieved new highs for the year.